Archive for the ‘Lyme’ Category

Two Prominent West Coast Lyme Clinics Merge

https://www.lymedisease.org/west-coast-lyme-clinics-merging/

Two prominent West Coast Lyme clinics are merging

by Dr. Eric Gordon

Every day, we work with patients with complex chronic illnesses. Each individual is a puzzle, with varying symptoms and overlapping medical concerns. We know how hard it is to have complex health issues and so much confusing information out there.

To continue to support our patients at the highest level, Gordon Medical Associates (GMA) is thrilled to share that in April, Dr. Steven Harris and Pacific Frontier Medical, Inc. (PFMI) is officially merging with us, making GMA the premier Lyme, tick-borne illness, and environmentally acquired illness clinic on the West Coast.

One of the key motivations behind this merger is the recognition of our complementary strengths. While PFMI has established itself as a leader in addressing Lyme and tick-borne diseases, GMA has a track record of treating a diverse range of complex conditions, including autoimmune disorders and mystery illnesses often linked to Lyme disease. By joining forces, we will leverage our expertise to offer an even deeper breadth of patient care than we each did alone.

A shared hallmark of both clinics is our focus on the psyche and intuition in healing paired with medical care. We understand that true healing goes beyond the physical realm and encompasses the emotional and spiritual well-being of our patients. This holistic philosophy guides our treatment protocols and ensures that each patient receives personalized care tailored to their unique needs.

Collaborative efforts

Central to our approach is the emphasis on teamwork. Each member of our team brings to the table a wealth of experience and insights gained from years of patient care and the learning that comes with it. We recognize the individuality and complexity of each case, and our collaborative efforts allow us to explore multiple facets and find innovative solutions.

The depth of our new team is enriched by the addition of specialists from the former PFMI, like Dr. Jen Sugden, an expert in women’s and children’s health. Moreover, both Yvonne Sorensen, PA, and Dr. Jen Sugden work extensively with PANS and PANDAS patients. Both practitioners bring invaluable insights into the treatment of neuroinflammatory diseases, which are increasingly affecting patients across different age groups.

Another exciting aspect of this merger is the integration of treatment modalities from both clinics. PFMI’s extensive experience with IVIG therapy complements GMA’s expertise in plasmapheresis and detoxification therapies. The combination of this knowledge will offer patients an even more comprehensive and sustainable approach to managing neuroinflammatory diseases.

The merger will also allow us at GMA to enhance our think tank for complex and chronic illness. In the past, we have all experienced excellent results working on our own. Now, we will be working collectively on more difficult cases.

I am looking forward to our weekly team meetings, where we discuss individual cases and new ideas, which will undoubtedly be enriched by the diverse perspectives and expertise of our combined team.

Personalized medicine

Dr. Harris and I have been delving into the critical necessity of personalized medicine through tailored research in highly complex cases. Our conversations often circle back to the limitations of current medical paradigms, particularly when confronted with the intricacies of complex biology and chronic illnesses. We firmly advocate for a shift towards dedicating more time to patient research, recognizing it as the key to unraveling the root causes and personalized biochemical responses behind various conditions.

In our discussions, we’ve candidly acknowledged the strain we’ve experienced from attempting to deliver personalized care within existing frameworks. It’s become apparent that without sufficient time for research, our efforts are constrained, leaving us feeling overworked and often unable to provide the level of individualized attention our patients deserve. This merger of both clinics will allow us more research time, which is often needed in highly complex cases.

Together, we are committed to advancing the field of integrative medicine and improving outcomes for our patients.

Dr. Eric Gordon is medical director of Gordon Medical Associates, in San Rafael, California.

Category:

Activism, Lyme

Evidence for the Presence of Borrelia Burgdorferi in Invasive Breast Cancer Tissues

https://www.researchgate.net/publication/378802154_Evidence_for_the_presence_of_Borrelia_burgdorferi_in_invasive_breast_cancer_tissues

Evidence for the presence of Borrelia burgdorferi in invasive breast cancer tissues

March 2024

DOI:10.1556/1886.2024.00021
Authors:  Niraj Jatin Patel, Sahaja Thippani, Jasmine Jathan, Gauri Gauri
Show all 7 authors
Download full-text PDF

Abstract

Borrelia burgdorferi , the causative agent of Lyme disease, has recently been demonstrated to infect and enhance the invasive properties of breast cancer cells, while also influencing the expression of inflammatory chemokines (CXCL8 and CXCL10). This study investigates the presence of B. burgdorferi in invasive breast cancer tissues using commercially available, FDA-approved breast cancer tissue microarrays consisting of 350 ductal, 32 lobular, and 22 intraductal invasive breast carcinomas, alongside 29 normal breast tissues. Employing fluorescent immunohistochemical staining and high-resolution imaging, the findings revealed that
  • approximately 20% of invasive lobular and ductal carcinomas, followed by
  • 14% of intraductal carcinomas, tested positive for B. burgdorferi,
  • while all normal breast tissues tested negative.
  • PCR analysis further confirmed the presence of B. burgdorferi DNA in breast cancer tissues.
  • Moreover, 25% of B. burgdorferi – positive tissues exhibited expression of both chemokines, CXCL8 and CXCL10, which was not observed in B. burgdorferi – negative tissues.
  • Analysis of available patient data, including age, indicated a correlation between older patients and B. burgdorferi – positive tissues.

This study validates the presence of B. burgdorferi in invasive breast cancer tissues and highlights the involvement of key CXCL family members associated with inflammatory processes.

_______________

**Comment**

It all of a sudden becomes quite clear why ‘the powers that be’ simply had to bury ivermectin and HCQ.  These drugs are turning out to be highly anti-viral and anti-cancer.  More and more is coming out on these safe, cheap drugs that have been effectively repurposed for cancer.  Due to a court order, the FDA had to remove its controversial verbiage on ivermectin from its website.  Predictably, the FDA claims no wrongdoing despite an estimated 500,000 deaths due to its suppression of ivermectin, as well as the fact doctors lost their jobs for simply endorsing the drug.

The FDA has a lot to answer for.

I also highly recommend reading and listening to this:  https://robertyoho.substack.com/p/302-how-to-save-your-life-if-you

On a personal side note relating to the above link: my holistic doctor (RIP) once told me that he successfully treated female cancers with testosterone and male cancers with estrogen.  At the time there weren’t any studies on this hormone approach for cancer and all he had to support it was his 35 years of clinical experience.  Now, it finally appears there are some studies:  https://hormonebalance.org/publications/

Another doctor we used has completely restored women who have severe endometriosis by using a cocktail of synthetic testosterones (nandrolone and stanozolol) that doesn’t break down into estrogen as well as the anti-androgen spironolactone to counter any facial hair or lowering of the voice.  My daughter still uses this treatment and it has worked amazingly for over ten years.  To say it has changed her life would be an understatement.

This too is a big reason hormone therapy is nearly banned in mainstream medicine.  It just does too many things for health which interferes with Big Pharma profits.

If you haven’t figured it out yet, the FDA could care less about true health.

For more:

Category:

Cancer, Inflammation, Lyme, research

Lyme Disease and the Fight for Recognition – A Documentary

http://  Approx. 43 Min

Lyme Disease and the Fight for Recognition

DW Documentary

April 7, 2023

Years of pain, paralysis and fear – without a diagnosis. For a long time, medicine seemed to ignore Lyme disease. The film accompanies several patients as they fight for an accurate diagnosis — and the right treatment. Many Lyme disease patients suffer for a long time before receiving a diagnosis. Their symptoms, including pain and paralysis, often seem to indicate other diseases, like MS. The fact that they have been bitten by a tick that carried Lyme disease often only emerges after many examinations.

This is exactly what happened to two of the film’s subjects: a girl from Brooklyn, NY and a researcher at Duke University. Both decided to take matters into their own hands and began carrying out independent research into their symptoms. Both ended up in the middle of a controversial medical debate and found themselves having to fight hard for adequate treatment.

For more:

TV Specials on Lyme

There’s been some excellent coverage of tick-borne illness, yet nothing changes.

Category:

Activism, Lyme

Bacterial Biofilm & Its Role in the Pathogenesis of Disease

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167820/

 2020 Feb; 9(2): 59.
Published online 2020 Feb 3. doi: 10.3390/antibiotics9020059
PMCID: PMC7167820
PMID: 32028684

Bacterial Biofilm and its Role in the Pathogenesis of Disease

Lene K. Vestby,1 Torstein Grønseth,2 Roger Simm,3 and Live L. Nesse4,*
Author information Article notes Copyright and License information PMC Disclaimer

Abstract

Recognition of the fact that bacterial biofilm may play a role in the pathogenesis of disease has led to an increased focus on identifying diseases that may be biofilm-related. Biofilm infections are typically chronic in nature, as biofilm-residing bacteria can be resilient to both the immune system, antibiotics, and other treatments. This is a comprehensive review describing biofilm diseases in the auditory, the cardiovascular, the digestive, the integumentary, the reproductive, the respiratory, and the urinary system. In most cases reviewed, the biofilms were identified through various imaging technics, in addition to other study approaches. The current knowledge on how biofilm may contribute to the pathogenesis of disease indicates a number of different mechanisms. This spans from biofilm being a mere reservoir of pathogenic bacteria, to playing a more active role, e.g., by contributing to inflammation. Observations also indicate that biofilm does not exclusively occur extracellularly, but may also be formed inside living cells. Furthermore, the presence of biofilm may contribute to development of cancer. In conclusion, this review shows that biofilm is part of many, probably most chronic infections. This is important knowledge for development of effective treatment strategies for such infections.

For more:

Category:

Biofilm, Inflammation, Lyme, research, Uncategorized

Obstetrical and Neonatal Outcomes in Women With Gestational Lyme Disease

https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.15380

Obstetrical and neonatal outcomes in women with gestational Lyme disease

First published: 21 January 2024
https://doi.org/10.1002/ijgo.15380
Read the full text

Abstract

Objective

The incidence of Lyme disease (LD) infections has risen in recent decades. Gestational LD has been associated with adverse pregnancy outcomes; however, the results have been contradictory. The study objective was to examine the effects of gestational LD on obstetrical and neonatal outcomes.

Methods

Using the Healthcare Cost & Utilization Project National (Nationwide) Inpatient Sample from the United States, we conducted a retrospective cohort study of pregnant patients admitted to the hospital between 2016 and 2019. The exposed group consisted of pregnant patients with gestational LD infection (International Classification of Diseases, Tenth Revision [ICD-10] code A692x), while the comparison group consisted of pregnant patients without gestational LD. Descriptive statistics and multivariate logistic regression models, adjusted for baseline maternal characteristics, were used to determine the associations between gestational LD and obstetrical and neonatal outcomes.

Results

The cohort included 2 ,943, 575 women, 226 of whom were diagnosed with LD during pregnancy. The incidence of LD was 7.67 per 100, 000 pregnancy admissions. The incidence of gestational LD was stable over the study period. Pregnant patients with LD were more likely white, older, to have private health insurance, and to belong to a higher income quartile. Gestational LD was associated with an increased risk of placental abruption (adjusted odds ratio [aOR], 3.45 [95% confidence interval (CI), 1.53–7.80]) and preterm birth (aOR, 1.58 [95% CI, 1.03–2.42]).

Conclusion

Gestational LD is associated with a higher risk of placental abruption and preterm birth. Pregnancies complicated by LD, while associated with a higher risk of certain adverse outcomes, can be followed in most healthcare settings.

_____________

For more:

Category:

Lyme, Pregnancy, research, Transmission